依达拉奉联合巴曲酶治疗急性脑梗死疗效观察

Efficacy of edaravone combined with batroxobin in treatment of patients with acute cerebral infarction

目的观察依达拉奉联合巴曲酶治疗急性脑梗死(acute cerebral infarction,ACI)的临床疗效。方法将65例发病6h以内的ACI患者随机分为两组,治疗组34例和对照组31例。对照组给予巴曲酶10、5、5U依次加入生理盐水250ml中,于入院第1、3、5天各静脉滴注1次,3次为一疗程,辅以马来酸桂哌齐特、胞二磷胆碱及降糖、降血脂、降血压等常规治疗;治疗组在此基础上加用依达拉奉30mg加入生理盐水100ml,2/d静脉滴注,连用14d。依据美国国立卫生院卒中量表(NIHSS)评分及日常生活能力评分(barthel index,BI)评定神经功能缺损程度。结果治疗组与对照组相比,NIHSS评分在治疗后1、2、3周差异具有统计学意义(P<0.05),BI分值在治疗后1、2、3周差异具有统计学意义(P<0.05)。结论 早期采用依达拉奉联合巴曲酶治疗ACI效果确切。

Objective To investigate the efficacy of edaravone combined with batroxoin in treatment of patients with acute cerebral infarction （ACI）. Methods Sixty - five ACI patients within 6 hours of onset were enrolled. They were randomly divided into study group （34 cases） and control group （31 cases）. The former received edaravone 30 rag, bid, for 14 days and batroxobin 10, 5, 5U qod while the latter was administrated with only batroxobin 10, 5, 5 U qod. The therapeutic effect was evaluated by the National Institutes of Health Stroke Scale （NIHSS） and the Bathal index （BI）. Results 1,2, 3 weeks after treatment, NIHSS was significantly different （ P 〈 0.05 ） between the study group and the control group, so were the data of BI. Conculsions Edaravone combined with batroxobin is an effective and safe therapy for ACI patients.